Showing 1381-1390 of 5062 results for "".
- Dermalogica Gives Back: Brand Launches Grant Program to Empower the Next Generation of Industry Proshttps://practicaldermatology.com/news/dermalogica-gives-back-brand-launches-grant-program-to-empower-the-next-generation-of-industry-pros/2461337/Dermalogica is offering a new grant program for non-profit organizations that help give greater access to skillset training in the United States. The grant program is now accepting applications and supports education, mentorship, and skills training for non-profits training therap
- Boehringer Ingelheim's Spevigo Is first Treatment FDA-Approved for GPPhttps://practicaldermatology.com/news/boehringer-ingelheims-spevigo-is-first-treatment-fda-approved-for-gpp/2461327/FDA has approved Spevigo (spesolimab) from Boehringer Ingelheim as the first approved treatment option for generalized pustular psoriasis (GPP) flares in adults. Spevigo is a novel, selective antibody that blocks the activation of the interleukin-36 receptor (IL-36R), a key part of a signali
- Psoriasis, Other Autoimmune Diseases Up Risk for CVDhttps://practicaldermatology.com/news/psoriasis-other-autoimmune-diseases-up-risk-for-cvd/2461323/Earlier research has suggested associations between some autoimmune disorders and a higher risk of cardiovascular disease, and now, a new study shows that nineteen of the most common autoimmune disorders seem to increase risk for developing heart disease. Patients with autoim
- Pulsed-Dye Laser Reduces the Effects of Hypertrophic Scars Post-thyroidectomyhttps://practicaldermatology.com/news/pulsed-dye-laser-reduces-the-effects-of-hypertrophic-scars-post-thyroidectomy/2461308/Treatment with a 595 nm pulsed dye laser (PDL) can prevent and improve hypertrophic scars in patients with post-thyroidectomy in a cost-effective fashion, a new study shows. For the study, 19 patients with hypertrophic scars after thyroidectomy underwent
- La Roche-Posay, American Cancer Society Partner to Improve Patient and Caregiver Quality of Lifehttps://practicaldermatology.com/news/la-roche-posay-american-cancer-partner-to-improve-patient-and-caregiver-quality-of-life/2461299/La Roche-Posay US is joining forces with the American Cancer Society (ACS) to further the support of cancer patients, survivors, caregivers, and the oncology community as well as raise awareness of cancer treatments' skin side effects. Since 1905, La Roche-Posay has been committed to improvin
- Epidural Nerve Block with Lidocaine Leads to Clearance of Psoriatic Skin Lesionshttps://practicaldermatology.com/news/epidural-nerve-block-with-lidocaine-leads-to-clearance-of-psoriatic-skin-lesions/2461297/Use of an epidural nerve block with lidocaine leads to clearance of psoriatic skin lesions, according to a novel proof-of-concept study in the Journal of Investigative Dermatology. “Case studies have shown that psoriasis patients have experienced significant symptom
- Third Harmonic Bio Appoints Thomas M. Soloway to its Board of Directorshttps://practicaldermatology.com/news/third-harmonic-bio-appoints-thomas-m-soloway-to-its-board-of-directors/2461292/Thomas M. Soloway is now a member of Third Harmonic Bio, Inc.’s Board of Directors. Mr. Soloway brings more than 25 years of experience in the life sciences industry, with senior roles in strategy, operations, corporate finance and venture capital to the company,
- FDA Approves JUVÉDERM VOLUX XC for Jawline Definitionhttps://practicaldermatology.com/news/fda-approved-juvederm-volux-xc-for-jawline-definition/2461286/The U.S. FDA has given its nod to JUVÉDERM VOLUX XC for the improvement of jawline definition in adults over the age of 21 with moderate to severe loss of jawline definition. "The approval of JUVÉDERM VOLUX XC represents the largest leap in innovation for ou
- Zoryve from Arcutis Approved for Plaque Psoriasishttps://practicaldermatology.com/news/zoryve-from-arcutis-approved-for-plaque-psoriasis/2461282/FDA has approved the New Drug Application (NDA) for Zoryve (roflumilast) cream 0.3% from Arcutis Biotherapeutics for the treatment of plaque psoriasis, including intertriginous areas, in patients 12 years of age or older. The first and only topical phosphodiesterase-4 (PDE4) inhib
- FDA Clears Use of Apyx Medical’s Renuvion Handpiece for Improvement in Appearance of Lax Skinhttps://practicaldermatology.com/news/fda-clears-use-of-apyx-medicals-renuvion-to-improve-appearance-of-lax-skin/2461273/The U.S. Food and Drug Administration received 510(k) clearance for the use of Apyx Medical’s Renuvion APR Handpiece for certain skin contraction procedures. Specifically, the Renuvion APR Handpieces are now indicated for use in subcutaneous dermatological and aest